Company refocusing connected the imaginable of its DECODE™ Platform to make transformative immune medicines
CAMBRIDGE, Mass., November 07, 2022--(BUSINESS WIRE)--Repertoire® Immune Medicines announced contiguous that Torben Straight Nissen has been appointed arsenic interim Chief Executive Officer, succeeding John Cox, who volition proceed with the institution successful an advisory role. With much than 2 decades of enactment experience, Straight Nissen joins the institution arsenic it shifts its resources and operations to absorption chiefly connected unlocking the imaginable of Repertoire’s DECODE™ Platform to make transformative immune medicines against caller immune targets successful cancer, autoimmune disorders, and infectious disease.
"I privation to convey John for his enactment and imaginativeness for harnessing the imaginable of the immune repertoire to make caller medicines," said Doug Cole, M.D., Chairman, Repertoire and Managing Partner, Flagship Pioneering. "As the archetypal CEO of Repertoire, John established the institution to present caller immune medicines to patients, and we volition proceed to physique upon this bold ambition."
Cole continued, "We invited Torben arsenic the adjacent CEO of Repertoire. His important acquisition starring and shaping platform-based biotech companies makes him well-positioned to thrust Repertoire guardant toward unlocking the imaginable of its DECODE platform."
"Repertoire has applied its proprietary DECODE level to make an unprecedented and unsocial knowing of the immune synapse. I americium energized by the accidental to leverage Repertoire’s almighty level to make caller and highly selective immune-based medicines for the attraction of cancer, autoimmune disorders, and infectious disease," said Straight Nissen. "I look guardant to moving with Repertoire’s awesome squad to supply caller and important therapies for patients with these diseases."
"The ngo of Repertoire is to observe the immune codes that thrust cellular immunity and to usage those codes to make caller immune medicines," said Cox. "Our caller discoveries of caller epitopes and T compartment receptors successful crab and autoimmune diseases show the committedness of the level that we built. I americium grateful to each subordinate of the Repertoire squad for making these advancements possible, and to the enactment squad that built this company. I look guardant to seeing Repertoire proceed its ngo to make a caller people of immune medicines nether Torben’s leadership."
About Torben Straight Nissen
Torben Straight Nissen is simply a elder spouse astatine Flagship Pioneering, contributing to Flagship’s strategical and operational objectives, including the origination of caller Flagship Labs companies. He is an experienced biotech entrepreneur and has been a subordinate of Flagship’s ecosystem since archetypal joining arsenic President of Rubius Therapeutics successful 2016. Prior to joining Flagship, Straight Nissen was astatine Pfizer wherever helium led Strategic Portfolio Management for the company’s worldwide R&D enactment and oversaw a portfolio spanning from find to Phase 2 crossed each large therapeutic areas. He has held enactment positions successful aggregate biotech companies, including Ascendis Pharma and Maxygen. Straight Nissen presently serves connected the committee of Axcella Health and is the founding CEO of FL84. He is besides a co-author oregon co-inventor of implicit 100 publications and published patents.
Company Update
In October, the institution stopped Phase 1 objective studies of its autologous multi-targeted T compartment therapeutic candidates, RPTR-147 and RPTR-168 successful quality papillomavirus (HPV) affirmative tumors. This followed an appraisal of caller information which showed that portion unchangeable illness was observed successful a tiny radical of patients, this effect was constricted and does not enactment advancing these programs.
The institution plans to use the translational insights from these studies to pass its ongoing improvement of caller treatments for coagulated tumors. These changes reposition the institution arsenic a pre-clinical enactment with reduced operational needs, and arsenic a result, the institution reduced its unit earlier this month.
Going forward, Repertoire volition absorption connected unlocking the imaginable of its proprietary DECODE level to make transformative medicines against caller immune targets successful cancer, autoimmune disorders and infectious disease.
About the DECODE™ Platform
The DECODE level is simply a almighty find motor that characterizes indispensable elements of the immune synapse. In particular, the level identifies T compartment receptor-antigen pairs successful the discourse of different important features of the immune synapse, specified arsenic T compartment relation and however antigens are presented by molecules connected antigen-presenting cells, known arsenic large quality leukocyte antigen, oregon HLA, molecules. Repertoire intends to utilize these insights into cardinal drivers that govern immune relation to plan and make caller immune merchandise candidates.
About Repertoire® Immune Medicines
Repertoire Immune Medicines is simply a biotechnology institution dedicated to creating treatments for diseases based connected the powerfulness of the quality T compartment repertoire to destruct crab cells, people pathogens and modulate immune relation successful autoimmune disease.
Our proprietary DECODETM level is designed to supply a broad knowing of the afloat repertoire of interactions betwixt T compartment receptors and their antigen targets that instrumentality spot erstwhile diseased cells are present. This analyzable and intricate biologic process is known arsenic the immune synapse. We judge the quality to decode these interactions represents 1 of the top opportunities for innovation successful aesculapian science.
Utilizing our DECODE platform, our extremity is to place the circumstantial T cell-antigen pairs that supply immune surveillance successful cancer, make representation responses to pathogens, and those that origin insubstantial harm successful autoimmune disease.
Repertoire was founded successful 2019 by Flagship Pioneering. Its squad operates from sites successful Cambridge, Massachusetts and Zurich, Switzerland and uses its DECODE exertion to rationally plan treatments for cancers, autoimmune disorders and infectious diseases.
To larn much astir Repertoire, delight sojourn our website: www.repertoire.com and travel america connected LinkedIn and Twitter.
View root mentation connected businesswire.com: https://www.businesswire.com/news/home/20221106005112/en/
Contacts
Catherine Falcetti
cfalcetti@repertoire.com
Olivia Offner
ooffner@flagshippioneering.com
English (US)